PubRank

Kwok-Kin Wong

Author PubWeight™ 261.92‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers. Nat Med 2008 14.47
2 High-throughput oncogene mutation profiling in human cancer. Nat Genet 2007 12.68
3 A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations. Cell 2010 11.20
4 A genome-wide RNAi screen identifies multiple synthetic lethal interactions with the Ras oncogene. Cell 2009 8.64
5 The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP. Proc Natl Acad Sci U S A 2008 8.08
6 LKB1 modulates lung cancer differentiation and metastasis. Nature 2007 7.80
7 Novel mutant-selective EGFR kinase inhibitors against EGFR T790M. Nature 2009 7.05
8 Sensitive mutation detection in heterogeneous cancer specimens by massively parallel picoliter reactor sequencing. Nat Med 2006 6.96
9 High-resolution genomic profiles of human lung cancer. Proc Natl Acad Sci U S A 2005 6.52
10 Chromosomally unstable mouse tumours have genomic alterations similar to diverse human cancers. Nature 2007 5.65
11 PF00299804, an irreversible pan-ERBB inhibitor, is effective in lung cancer models with EGFR and ERBB2 mutations that are resistant to gefitinib. Cancer Res 2007 5.45
12 The impact of human EGFR kinase domain mutations on lung tumorigenesis and in vivo sensitivity to EGFR-targeted therapies. Cancer Cell 2006 5.34
13 Predicting drug susceptibility of non-small cell lung cancers based on genetic lesions. J Clin Invest 2009 5.07
14 Bronchial and peripheral murine lung carcinomas induced by T790M-L858R mutant EGFR respond to HKI-272 and rapamycin combination therapy. Cancer Cell 2007 4.85
15 Mutations in the DDR2 kinase gene identify a novel therapeutic target in squamous cell lung cancer. Cancer Discov 2011 4.80
16 A novel ALK secondary mutation and EGFR signaling cause resistance to ALK kinase inhibitors. Cancer Res 2011 4.22
17 The myeloma drug lenalidomide promotes the cereblon-dependent destruction of Ikaros proteins. Science 2013 4.20
18 Differential induction of apoptosis in HER2 and EGFR addicted cancers following PI3K inhibition. Proc Natl Acad Sci U S A 2009 4.02
19 Integrative genomic and proteomic analyses identify targets for Lkb1-deficient metastatic lung tumors. Cancer Cell 2010 3.40
20 Synthetic lethal interaction of combined BCL-XL and MEK inhibition promotes tumor regressions in KRAS mutant cancer models. Cancer Cell 2012 3.39
21 Drug-sensitive FGFR2 mutations in endometrial carcinoma. Proc Natl Acad Sci U S A 2008 3.30
22 Activation of the PD-1 pathway contributes to immune escape in EGFR-driven lung tumors. Cancer Discov 2013 3.25
23 A murine lung cancer co-clinical trial identifies genetic modifiers of therapeutic response. Nature 2012 3.24
24 EZH2 is required for germinal center formation and somatic EZH2 mutations promote lymphoid transformation. Cancer Cell 2013 3.13
25 Functional analysis of receptor tyrosine kinase mutations in lung cancer identifies oncogenic extracellular domain mutations of ERBB2. Proc Natl Acad Sci U S A 2012 3.06
26 Telomere shortening and mood disorders: preliminary support for a chronic stress model of accelerated aging. Biol Psychiatry 2006 2.85
27 GOLPH3 modulates mTOR signalling and rapamycin sensitivity in cancer. Nature 2009 2.77
28 Identifying genotype-dependent efficacy of single and combined PI3K- and MAPK-pathway inhibition in cancer. Proc Natl Acad Sci U S A 2009 2.77
29 An alternative inhibitor overcomes resistance caused by a mutation of the epidermal growth factor receptor. Cancer Res 2005 2.72
30 Combined use of ALK immunohistochemistry and FISH for optimal detection of ALK-rearranged lung adenocarcinomas. J Thorac Oncol 2013 2.68
31 Characterization of the cell of origin for small cell lung cancer. Cell Cycle 2011 2.62
32 Reactivation of ERK signaling causes resistance to EGFR kinase inhibitors. Cancer Discov 2012 2.47
33 Mutations in BRAF and KRAS converge on activation of the mitogen-activated protein kinase pathway in lung cancer mouse models. Cancer Res 2007 2.45
34 Compromised CDK1 activity sensitizes BRCA-proficient cancers to PARP inhibition. Nat Med 2011 2.35
35 Somatic LKB1 mutations promote cervical cancer progression. PLoS One 2009 2.21
36 Inhibition of ALK, PI3K/MEK, and HSP90 in murine lung adenocarcinoma induced by EML4-ALK fusion oncogene. Cancer Res 2010 2.20
37 Receptor tyrosine kinases exert dominant control over PI3K signaling in human KRAS mutant colorectal cancers. J Clin Invest 2011 2.20
38 Epidermal growth factor receptor variant III mutations in lung tumorigenesis and sensitivity to tyrosine kinase inhibitors. Proc Natl Acad Sci U S A 2006 2.17
39 Exploiting cancer cell vulnerabilities to develop a combination therapy for ras-driven tumors. Cancer Cell 2011 2.17
40 An ErbB3 antibody, MM-121, is active in cancers with ligand-dependent activation. Cancer Res 2010 2.14
41 Allele-dependent variation in the relative cellular potency of distinct EGFR inhibitors. Cancer Biol Ther 2007 2.12
42 Proapoptotic BH3-only BCL-2 family protein BIM connects death signaling from epidermal growth factor receptor inhibition to the mitochondrion. Cancer Res 2007 2.10
43 Hsp90 inhibition suppresses mutant EGFR-T790M signaling and overcomes kinase inhibitor resistance. Cancer Res 2008 1.95
44 A multicenter phase II study of ganetespib monotherapy in patients with genotypically defined advanced non-small cell lung cancer. Clin Cancer Res 2013 1.90
45 Metformin prevents liver tumorigenesis by inhibiting pathways driving hepatic lipogenesis. Cancer Prev Res (Phila) 2012 1.90
46 Primary tumor genotype is an important determinant in identification of lung cancer propagating cells. Cell Stem Cell 2010 1.81
47 Multiple roles of cyclin-dependent kinase 4/6 inhibitors in cancer therapy. J Natl Cancer Inst 2012 1.81
48 Mitigation of hematologic radiation toxicity in mice through pharmacological quiescence induced by CDK4/6 inhibition. J Clin Invest 2010 1.74
49 Loss of Lkb1 provokes highly invasive endometrial adenocarcinomas. Cancer Res 2008 1.67
50 Sunitinib prolongs survival in genetically engineered mouse models of multistep lung carcinogenesis. Cancer Prev Res (Phila) 2009 1.67
51 Resistance to irreversible EGF receptor tyrosine kinase inhibitors through a multistep mechanism involving the IGF1R pathway. Cancer Res 2012 1.66
52 Non-small-cell lung cancer and Ba/F3 transformed cells harboring the ERBB2 G776insV_G/C mutation are sensitive to the dual-specific epidermal growth factor receptor and ERBB2 inhibitor HKI-272. Cancer Res 2006 1.58
53 Efficacy of BET bromodomain inhibition in Kras-mutant non-small cell lung cancer. Clin Cancer Res 2013 1.56
54 HER2YVMA drives rapid development of adenosquamous lung tumors in mice that are sensitive to BIBW2992 and rapamycin combination therapy. Proc Natl Acad Sci U S A 2009 1.56
55 Inhibitor-sensitive FGFR2 and FGFR3 mutations in lung squamous cell carcinoma. Cancer Res 2013 1.51
56 HIF2alpha cooperates with RAS to promote lung tumorigenesis in mice. J Clin Invest 2009 1.49
57 LKB1/STK11 inactivation leads to expansion of a prometastatic tumor subpopulation in melanoma. Cancer Cell 2012 1.49
58 A genetic screen identifies an LKB1-MARK signalling axis controlling the Hippo-YAP pathway. Nat Cell Biol 2013 1.41
59 Dual targeting of the PI3K/Akt/mTOR pathway as an antitumor strategy in Waldenstrom macroglobulinemia. Blood 2009 1.40
60 DNA-dependent protein kinase catalytic subunit is not required for dysfunctional telomere fusion and checkpoint response in the telomerase-deficient mouse. Mol Cell Biol 2006 1.39
61 Alu elements mediate MYB gene tandem duplication in human T-ALL. J Exp Med 2007 1.37
62 The pivotal role of IKKα in the development of spontaneous lung squamous cell carcinomas. Cancer Cell 2013 1.36
63 HIF1α and HIF2α independently activate SRC to promote melanoma metastases. J Clin Invest 2013 1.32
64 Tumor-propagating cells and Yap/Taz activity contribute to lung tumor progression and metastasis. EMBO J 2014 1.30
65 Metabolic and functional genomic studies identify deoxythymidylate kinase as a target in LKB1-mutant lung cancer. Cancer Discov 2013 1.27
66 Combined EGFR/MET or EGFR/HSP90 inhibition is effective in the treatment of lung cancers codriven by mutant EGFR containing T790M and MET. Cancer Res 2012 1.27
67 Lkb1 inactivation is sufficient to drive endometrial cancers that are aggressive yet highly responsive to mTOR inhibitor monotherapy. Dis Model Mech 2010 1.27
68 Ganetespib (STA-9090), a nongeldanamycin HSP90 inhibitor, has potent antitumor activity in in vitro and in vivo models of non-small cell lung cancer. Clin Cancer Res 2012 1.26
69 Inhibition of KRAS-driven tumorigenicity by interruption of an autocrine cytokine circuit. Cancer Discov 2014 1.26
70 Therapeutic anti-EGFR antibody 806 generates responses in murine de novo EGFR mutant-dependent lung carcinomas. J Clin Invest 2007 1.26
71 A dual role for the immune response in a mouse model of inflammation-associated lung cancer. J Clin Invest 2011 1.25
72 KDM2B promotes pancreatic cancer via Polycomb-dependent and -independent transcriptional programs. J Clin Invest 2013 1.21
73 Activation of FOXO3a is sufficient to reverse mitogen-activated protein/extracellular signal-regulated kinase kinase inhibitor chemoresistance in human cancer. Cancer Res 2010 1.20
74 Characterization of Torin2, an ATP-competitive inhibitor of mTOR, ATM, and ATR. Cancer Res 2013 1.16
75 Activating Mutations in ERBB2 and Their Impact on Diagnostics and Treatment. Front Oncol 2013 1.14
76 Lysine-specific demethylase 2B (KDM2B)-let-7-enhancer of zester homolog 2 (EZH2) pathway regulates cell cycle progression and senescence in primary cells. J Biol Chem 2011 1.12
77 Suppression of heat shock protein 27 induces long-term dormancy in human breast cancer. Proc Natl Acad Sci U S A 2012 1.12
78 New cast for a new era: preclinical cancer drug development revisited. J Clin Invest 2013 1.11
79 Integrative radiogenomic profiling of squamous cell lung cancer. Cancer Res 2013 1.10
80 Regression of drug-resistant lung cancer by the combination of rosiglitazone and carboplatin. Clin Cancer Res 2008 1.09
81 Cigarette smoking increases copy number alterations in nonsmall-cell lung cancer. Proc Natl Acad Sci U S A 2011 1.05
82 Summary statement: novel agents in the treatment of lung cancer: advances in epidermal growth factor receptor-targeted agents. Clin Cancer Res 2006 1.03
83 Differences underlying EGFR and HER2 oncogene addiction. Cell Cycle 2010 1.02
84 Cetuximab response of lung cancer-derived EGF receptor mutants is associated with asymmetric dimerization. Cancer Res 2013 1.00
85 Targeting an IKBKE cytokine network impairs triple-negative breast cancer growth. J Clin Invest 2014 1.00
86 Telomere dysfunction promotes genome instability and metastatic potential in a K-ras p53 mouse model of lung cancer. Carcinogenesis 2008 0.99
87 D-2-hydroxyglutarate produced by mutant IDH2 causes cardiomyopathy and neurodegeneration in mice. Genes Dev 2014 0.97
88 Mouse models of lung cancer. Clin Cancer Res 2006 0.95
89 Temporal molecular and biological assessment of an erlotinib-resistant lung adenocarcinoma model reveals markers of tumor progression and treatment response. Cancer Res 2012 0.95
90 Preexisting oncogenic events impact trastuzumab sensitivity in ERBB2-amplified gastroesophageal adenocarcinoma. J Clin Invest 2014 0.92
91 RMRP is a non-coding RNA essential for early murine development. PLoS One 2011 0.91
92 The age of cancer: telomeres, checkpoints, and longevity. J Clin Invest 2003 0.91
93 BAC consensus conference, November 4-6, 2004: epidemiology, pathogenesis, and preclinical models. J Thorac Oncol 2006 0.90
94 CDK4/6 inhibition induces epithelial cell cycle arrest and ameliorates acute kidney injury. Am J Physiol Renal Physiol 2013 0.89
95 Differential roles of telomere attrition in type I and II endometrial carcinogenesis. Am J Pathol 2008 0.89
96 Design and generation of MLPA probe sets for combined copy number and small-mutation analysis of human genes: EGFR as an example. ScientificWorldJournal 2010 0.89
97 Development of Selective Covalent Janus Kinase 3 Inhibitors. J Med Chem 2015 0.87
98 EGFR targeted therapy: view from biological standpoint. Cell Cycle 2006 0.87
99 Magnetic resonance imaging of the response of a mouse model of non-small cell lung cancer to tyrosine kinase inhibitor treatment. Comp Med 2008 0.84
100 Novel agents in the treatment of lung cancer: Fourth Cambridge Conference. Clin Cancer Res 2007 0.83
101 The LKB1 tumor suppressor as a biomarker in mouse and human tissues. PLoS One 2013 0.83
102 LKB1 loss promotes endometrial cancer progression via CCL2-dependent macrophage recruitment. J Clin Invest 2015 0.82
103 STOP gene Phactr4 is a tumor suppressor. Proc Natl Acad Sci U S A 2013 0.82
104 Temporal dissection of K-ras(G12D) mutant in vitro and in vivo using a regulatable K-ras(G12D) mouse allele. PLoS One 2012 0.81
105 Walking the telomere plank into cancer. J Natl Cancer Inst 2003 0.80
106 Loss of p53 attenuates the contribution of IL-6 deletion on suppressed tumor progression and extended survival in Kras-driven murine lung cancer. PLoS One 2013 0.80
107 Integrative genomic analysis reveals a high frequency of LKB1 genetic alteration in Chinese lung adenocarcinomas. J Thorac Oncol 2014 0.79
108 Molecular determinants of response to matuzumab in combination with paclitaxel for patients with advanced non-small cell lung cancer. Mol Cancer Ther 2009 0.79
109 Chromosomal end fusion resulting from telomere erosion increases susceptibility to radiation via multinucleation: effect of p53. Int J Oncol 2006 0.75
110 Acquired substrate preference for GAB1 protein bestows transforming activity to ERBB2 kinase lung cancer mutants. J Biol Chem 2013 0.75
111 Erratum: Lkb1 inactivation drives lung cancer lineage switching governed by Polycomb Repressive Complex 2. Nat Commun 2017 0.75
112 Corrigendum: Mutant IDH inhibits HNF-4α to block hepatocyte differentiation and promote biliary cancer. Nature 2015 0.75